Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06064838




Registration number
NCT06064838
Ethics application status
Date submitted
2/10/2023
Date registered
3/10/2023
Date last updated
1/10/2024

Titles & IDs
Public title
Effects of Cacao Flavonoids in Long COVID-19 Patients (FLALOC)
Scientific title
Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue (FLALOC)
Secondary ID [1] 0 0
FLALOC
Universal Trial Number (UTN)
Trial acronym
FLALOC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Long Covid19 0 0
Fatigue Syndrome, Chronic 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Other 0 0 0 0
Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Flavonoids

Experimental: Flavonoids - Capsules with 500mg of cacao flavonoids, twice a day for 90 days

Placebo comparator: Placebo - Capsules with 500mg of excipients, twice a day for 90 days


Treatment: Other: Flavonoids
1 capsule every 12h for 90 days
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Interleukin-1b
Timepoint [1] 0 0
At 0 and 90 day
Primary outcome [2] 0 0
Interleukin-6
Timepoint [2] 0 0
At 0 and 90 day
Primary outcome [3] 0 0
TNF-alpha
Timepoint [3] 0 0
At 0 and 90 day
Primary outcome [4] 0 0
Syndecan-1
Timepoint [4] 0 0
At 0 and 90 day
Secondary outcome [1] 0 0
EQ-5D questionnaire
Timepoint [1] 0 0
At 0 and 90 day
Secondary outcome [2] 0 0
Analog Visual Scale
Timepoint [2] 0 0
At 0 and 90 day
Secondary outcome [3] 0 0
Numerical fatigue rating scale
Timepoint [3] 0 0
At 0 and 90 day
Secondary outcome [4] 0 0
Handgrip strength
Timepoint [4] 0 0
At 0 and 90 day

Eligibility
Key inclusion criteria
* Post-COVID-19 patients, at least 6 months after symptom onset
* Chronic fatigue
Minimum age
30 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Allergy or intolerance caused by active ingredients
* Pregnancy or lactation
* BMI >35
* chronic liver disease
* chronic kidney disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/09/2024
Sample size
Target
Accrual to date
Final
46
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Mexico
State/province [1] 0 0
Mexico City

Funding & Sponsors
Primary sponsor type
Other
Name
Guillermo Ceballos Reyes
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06064838